The partnership seeks to streamline authorization pathways and advocate for broader access to neurostimulator therapies for obstructive sleep apnea.

Nyxoah SA, maker of the CE-marked Genio neurostimulator for obstructive sleep apnea (OSA), signed a strategic partnership to become a corporate champion at the ENTerprise Circle level with the American Association of Otolaryngology – Head & Neck Surgery Foundation (AAO-HNSF). 

Nyxoah is the first medical device company to partner with the AAO-HNSF at this level.

The AAO-HNSF is committed to identifying and combating harmful coverage policies that threaten access to quality otolaryngology-head and neck services. The Academy’s Advocacy team, in collaboration with its members and industry partners like Nyxoah, actively engage with payers to achieve this goal.

The ENTerprise Circle is the top-tier partnership experience, and the collaboration will focus on improving patient access to new treatments for OSA by:

  • Navigating the Centers for Medicare & Medicaid Services (CMS) and private payers prior authorization requirements pathway
  • Preparing for interaction with the US Food and Drug Administration and American Medical Association’s Current Procedural Terminology to expand patient access to appropriate care
  • Advocating for reducing the hurdles to new, bilateral hypoglossal nerve stimulation (HGNS) therapy with clinical guidelines to be used by CMS and commercial insurance payers

“We are thrilled to partner with Nyxoah, the maker of Genio,” says James Denneny III, MD, executive vice president and CEO of AAO-HNSF in a release. “With the rapid growth of HGNS, ENTs are playing an increasingly important role in treating OSA. Genio represents the next generation of HGNS technology, and the AAO-HNSF looks forward to working closely with Nyxoah to ensure all patients in the US have access to the system.”

Olivier Taelman, Nyxoah’s CEO, adds in a release, “We are honored to be the first medical device company to partner with the AAO-HNSF as a corporate champion at the ENTerprise Circle level. Nyxoah and the AAO-HNSF share the common goal of putting patients first and making sure they have access to HGNS therapy. We look forward to working closely with the AAO-HNSF as we prepare for our US launch.”

Illustration 188777935 © Skypixel |